Top Markets
Coin of the day
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Classificação em ações #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Preço da ação
$8.74
Última sincronização: 2026-08-28
Valor de mercado
$699.74M
Variação (1 dia)
-4.85%
Variação (1 ano)
-2.29%
País
US
Negociar BridgeBio Oncology Therapeutics Inc. (BBOT)

Categoria

Histórico de preços das ações de BridgeBio Oncology Therapeutics Inc. (BBOT)
Preço de fecho mais alto: $9.16 em 2026-08-01

Preço de fecho mais baixo: $10.40 em 2024-02-01
Histórico de preços das ações da BridgeBio Oncology Therapeutics Inc. de 2024 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) -16.90%
2025 15.50%
2024 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.53 -12.70%
AU
$138.18 473.58%
US
$759.27 7.20%
CH